**Supplemental Figure 1. Percentage of Patients Achieving Relevant ALP Thresholds (Period 1) Excluding Patients with Day 0 ALP <1.5x ULN**



ALP: alkaline phosphatase; BID: twice daily.

Four patients (placebo, n=2; HTD1801 1000 mg BID, n=2) who had a screening ALP >1.5x ULN, but Day 0 ALP <1.5x ULN were excluded from this analysis.

**Supplemental Figure 2. Waterfall Plots by Treatment Group and Prior UDCA Usage**



ALP: alkaline phosphatase; BID: twice daily; UDCA: ursodeoxycholic acid.

Each bar represents an individual patient’s change from baseline to Week 6 in ALP.

**Supplemental Table 1. Concomitant Medications Received for the Treatment of IBD**

| **Medication Received** | **n (%)\*** |
| --- | --- |
| Mesalazine | 15 (27%) |
| Sulfasalazine | 1 (2%) |
| Budesonide | 3 (5%) |
| Methotrexate Sodium | 1 (2%) |
| Prednisone | 1 (2%) |
| Ustekinumab | 1 (2%) |
| Mercaptopurine | 1 (2%) |
| Vedolizumab | 3 (5%) |
| Tofacitinib | 1 (2%) |
| Adalimumab | 2 (4%) |
| Infliximab | 2 (4%) |

\*Percentages are based on the total study population